Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects

Area of Science:

• Cardiovascular Disease Research
• Inflammation and Immunology
• Metabolic Disorders

Background:

• Elevated plasma homocysteine is an independent risk factor for cardiovascular disease, but the underlying mechanisms remain unclear.
• High-sensitivity C-reactive protein (CRP) and Interleukin-6 (IL-6) are key markers and mediators of inflammation, respectively.
• IL-6 is a crucial regulator of CRP and plays a significant role in initiating inflammatory responses.

Purpose of the Study:

• To investigate the association between elevated plasma homocysteine concentrations and serum levels of CRP and IL-6.
• To explore the potential role of inflammation in hyperhomocysteinemia-related vascular disease.

Main Methods:

• Serum CRP and IL-6 concentrations were measured in 39 hyperhomocysteinemic individuals and 39 matched controls.
• The inflammatory effect of IL-6 on peripheral blood mononuclear cells was assessed.
• Participants were matched for gender, age, and body mass index (BMI).

Main Results:

• Hyperhomocysteinemic subjects exhibited significantly elevated serum levels of both CRP and IL-6 compared to controls (p < 0.001 and p < 0.005, respectively).
• Increased IL-6 levels were observed even in hyperhomocysteinemic individuals without hypercholesterolemia or existing cardiovascular disease.
• IL-6 enhanced the release of monocyte chemoattractant protein-1 from peripheral blood mononuclear cells, with a more pronounced effect in cells from hyperhomocysteinemic patients.

Conclusions:

• Enhanced inflammation, potentially mediated by IL-6, is associated with homocysteine-related cardiovascular disease.
• These findings suggest a mechanistic link between hyperhomocysteinemia, inflammation, and cardiovascular risk.
• Further research into IL-6-related pathways may reveal novel therapeutic targets for cardiovascular disease prevention in hyperhomocysteinemic individuals.